Idex (IEX) reported $814.3 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 1.7%. EPS of $1.75 for the same period compares to $1.88 a year ago.
The reported revenue represents a surprise of +1.36% over the Zacks Consensus Estimate of $803.37 million. With the consensus EPS estimate being $1.64, the EPS surprise was +6.71%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Idex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net sales - Organic impact - YoY change: -1% compared to the -3.5% average estimate based on two analysts.
- Net Sales- Fluid & Metering Technologies (FMT): $290.50 million compared to the $288.77 million average estimate based on three analysts. The reported number represents a change of -7.4% year over year.
- Intersegment sales eliminations: -$2 million versus -$1.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +53.9% change.
- Net Sales- Fire & Safety/Diversified Products (FSDP): $184.30 million versus the three-analyst average estimate of $177.49 million. The reported number represents a year-over-year change of +3.5%.
- Net Sales- Health & Science Technologies (HST): $341.50 million versus the three-analyst average estimate of $338.03 million. The reported number represents a year-over-year change of +10.1%.
- Adjusted EBITDA- Fluid & Metering Technologies (FMT): $95.30 million versus the two-analyst average estimate of $91.20 million.
- Adjusted EBITDA- Corporate: -$28.90 million versus -$32.55 million estimated by two analysts on average.
- Adjusted EBITDA- Fire & Safety/Diversified Products (FSDP): $54.20 million versus $51 million estimated by two analysts on average.
- Adjusted EBITDA- Health & Science Technologies (HST): $87.40 million versus $86 million estimated by two analysts on average.
View all Key Company Metrics for Idex here>>>
Shares of Idex have returned -5.1% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IDEX Corporation (IEX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
